دورية أكاديمية
Roles of Major RNA Adenosine Modifications in Head and Neck Squamous Cell Carcinoma.
| العنوان: | Roles of Major RNA Adenosine Modifications in Head and Neck Squamous Cell Carcinoma. |
|---|---|
| المؤلفون: | Huo XX; Experimental Center of Clinical Research, Scientific Research Department, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, China.; Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, China., Wang SJ; Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, China., Song H; Department of Biochemistry and Molecular Biology, School of Integrated Chinese and Western Medicine, Anhui University of Chinese Medicine, Hefei, China., Li MD; Experimental Center of Clinical Research, Scientific Research Department, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, China., Yu H; Institute of Chinese Medical Sciences, State Key Laboratory of Quality Research in Chinese Medicine, University of Macau, Macao, China., Wang M; Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, China., Gong HX; Experimental Center of Clinical Research, Scientific Research Department, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, China., Qiu XT; Experimental Center of Clinical Research, Scientific Research Department, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, China., Zhu YF; Experimental Center of Clinical Research, Scientific Research Department, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, China., Zhang JY; Key Laboratory of Molecular Target and Clinical Pharmacology and the State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences and the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China. |
| المصدر: | Frontiers in pharmacology [Front Pharmacol] 2021 Nov 25; Vol. 12, pp. 779779. Date of Electronic Publication: 2021 Nov 25 (Print Publication: 2021). |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Media] |
| مستخلص: | Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer malignancy worldwide and is known to have poor prognosis. The pathogenesis behind the development of HNSCC is not fully understood. Modifications on RNA are involved in many pathophysiological processes, such as tumor development and inflammation. Adenosine-related RNA modifications have shown to be linked to cancer and may play a role in cancer occurrence and development. To date, there are at least 170 different chemical RNA modifications that modify coding and non-coding RNAs (ncRNAs). These modifications affect RNA stability and transcription efficiency. In this review, we focus on the current understanding of the four major RNA adenosine modifications (N 6 -Methyladenosine, N 1 -Methyladenosine, Alternative Polyadenylation Modification and A-to-I RNA editing) and their potential molecular mechanisms related to HNSCC development and progression. We also touch on how these RNA modifications affect treatment of HNSCCs. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2021 Huo, Wang, Song, Li, Yu, Wang, Gong, Qiu, Zhu and Zhang.) |
| References: | Apoptosis. 2020 Apr;25(3-4):233-246. (PMID: 31974865) J Exp Clin Cancer Res. 2019 Dec 18;38(1):497. (PMID: 31852504) Annu Rev Biochem. 2010;79:321-49. (PMID: 20192758) Oncogene. 2018 Aug;37(35):4887-4900. (PMID: 29780166) Cancer Res Treat. 2021 Jul;53(3):671-677. (PMID: 33285051) Cancer Cell Int. 2020 May 29;20:203. (PMID: 32514248) Cancer Sci. 2020 Jun;111(6):1991-2003. (PMID: 32232887) Mol Med Rep. 2014 May;9(5):1597-605. (PMID: 24604236) Sci Rep. 2017 Feb 13;7:42271. (PMID: 28205560) Nature. 2017 Nov 9;551(7679):251-255. (PMID: 29072297) Nat Genet. 2008 Dec;40(12):1413-5. (PMID: 18978789) J Biol Chem. 2017 Sep 1;292(35):14695-14703. (PMID: 28655767) Nat Rev Genet. 2019 Oct;20(10):599-614. (PMID: 31267064) Nat Commun. 2014 Nov 20;5:5274. (PMID: 25409906) Biochemistry. 2000 Oct 24;39(42):12875-84. (PMID: 11041852) Cell Physiol Biochem. 2018;51(4):1945-1956. (PMID: 30513526) Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):E4631-E4640. (PMID: 28533408) Neurosci Res. 2019 Oct;147:48-57. (PMID: 30448461) Nucleic Acids Res. 2012 Sep 1;40(17):8460-71. (PMID: 22753024) Cell Physiol Biochem. 2018;47(6):2602-2612. (PMID: 29996118) Nature. 2015 Jun 18;522(7556):363-7. (PMID: 25896326) Front Cell Neurosci. 2019 Jan 10;12:518. (PMID: 30687010) Genes Dev. 1995 Nov 1;9(21):2672-83. (PMID: 7590244) J Mol Cell Cardiol. 2021 Nov;160:111-120. (PMID: 34302813) Cell Rep. 2012 Jun 28;1(6):753-63. (PMID: 22813749) Arch Dermatol Res. 2013 Aug;305(6):519-28. (PMID: 23543219) Science. 2012 Dec 14;338(6113):1435-9. (PMID: 23239728) Cancer Lett. 2017 Dec 1;410:158-168. (PMID: 28964783) PLoS One. 2020 May 21;15(5):e0233380. (PMID: 32437477) Onco Targets Ther. 2020 Feb 21;13:1605-1612. (PMID: 32158230) Neoplasia. 2006 Dec;8(12):1003-10. (PMID: 17217617) Cell Rep. 2015 Oct 13;13(2):277-89. (PMID: 26440892) J Biol Chem. 1995 Feb 10;270(6):2800-8. (PMID: 7852352) Genome Biol. 2017 Oct 31;18(1):204. (PMID: 29084609) Mol Cell. 2019 May 16;74(4):640-650. (PMID: 31100245) Nucleic Acids Res. 2018 Sep 6;46(15):7953-7969. (PMID: 29796672) Nat Commun. 2021 Feb 16;12(1):1047. (PMID: 33594075) Annu Rev Biochem. 2002;71:817-46. (PMID: 12045112) RNA Biol. 2010 Mar-Apr;7(2):253-62. (PMID: 20215858) Mol Ther Nucleic Acids. 2020 Sep 4;21:299-314. (PMID: 32622331) Wiley Interdiscip Rev RNA. 2019 Jul;10(4):e1526. (PMID: 30816016) Front Oncol. 2020 May 29;10:718. (PMID: 32547941) Curr Opin Hematol. 2019 Jul;26(4):241-248. (PMID: 31033705) PeerJ. 2020 Nov 26;8:e10385. (PMID: 33304653) Nat Rev Mol Cell Biol. 2017 Jan;18(1):18-30. (PMID: 27677860) Cancer Cell. 2015 Oct 12;28(4):515-528. (PMID: 26439496) Cancer Res. 2019 Nov 15;79(22):5785-5798. (PMID: 31530567) Mol Oncol. 2020 Jun;14(6):1282-1296. (PMID: 32216017) Theranostics. 2020 Aug 21;10(23):10531-10547. (PMID: 32929364) J Exp Clin Cancer Res. 2021 Feb 26;40(1):80. (PMID: 33637103) J Immunother Cancer. 2018 Jan 23;6(1):8. (PMID: 29357948) Biosci Rep. 2021 Apr 30;41(4):. (PMID: 33779693) RNA. 2001 Jun;7(6):846-58. (PMID: 11421361) J Oral Pathol Med. 2019 Feb;48(2):108-114. (PMID: 30489667) Sci Rep. 2016 Mar 16;6:23226. (PMID: 26980570) J Cell Sci. 2017 Feb 15;130(4):745-753. (PMID: 28082424) CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338) Front Oncol. 2021 Mar 18;11:629718. (PMID: 33816266) Adv Exp Med Biol. 2014;825:97-127. (PMID: 25201104) Arch Oral Biol. 2021 Feb;122:105030. (PMID: 33383437) Carbohydr Polym. 2019 Feb 1;205:540-549. (PMID: 30446138) Cancer Cytopathol. 2021 Aug 10;:. (PMID: 34375025) Eur Rev Med Pharmacol Sci. 2020 Apr;24(8):4328-4336. (PMID: 32373970) Nucleic Acids Res. 2012 Dec;40(22):11583-93. (PMID: 23042678) Wiley Interdiscip Rev RNA. 2011 May-Jun;2(3):348-61. (PMID: 21957022) Oral Oncol. 2021 Oct;121:105472. (PMID: 34333450) Nat Immunol. 2009 Jan;10(1):48-57. (PMID: 19011627) Nat Rev Dis Primers. 2020 Nov 26;6(1):92. (PMID: 33243986) Cancer Cell Int. 2020 Dec 7;20(1):585. (PMID: 33372610) J Clin Oncol. 2009 Apr 10;27(11):1864-71. (PMID: 19289630) Nucleic Acids Res. 2017 Jul 7;45(12):7401-7415. (PMID: 28472312) Theranostics. 2019 Sep 23;9(24):7156-7167. (PMID: 31695759) Nat Chem Biol. 2016 May;12(5):311-6. (PMID: 26863410) J Exp Clin Cancer Res. 2019 Jul 17;38(1):315. (PMID: 31315644) Anal Chem. 2018 Jun 5;90(11):6380-6384. (PMID: 29791134) Nanoscale Horiz. 2021 Sep 1;6(9):729-743. (PMID: 34323910) N Engl J Med. 2008 Sep 11;359(11):1116-27. (PMID: 18784101) Brief Bioinform. 2019 Jan 18;20(1):102-109. (PMID: 28968662) Sci Rep. 2018 Oct 4;8(1):14848. (PMID: 30287844) Nat Methods. 2019 Nov;16(11):1131-1138. (PMID: 31636457) Int J Oncol. 2017 Feb;50(2):622-630. (PMID: 28035363) Ann Oncol. 2014 Apr;25(4):801-807. (PMID: 24577117) Nature. 2008 Nov 27;456(7221):470-6. (PMID: 18978772) Oral Dis. 2021 Aug 17;:. (PMID: 34403535) J Exp Clin Cancer Res. 2019 Feb 7;38(1):61. (PMID: 30732622) Cancer Cell Int. 2019 Dec 2;19:321. (PMID: 31827395) Am J Cancer Res. 2021 Jul 15;11(7):3688-3697. (PMID: 34354868) Transl Oncol. 2019 Oct;12(10):1323-1333. (PMID: 31352195) Med Sci Monit. 2019 Feb 24;25:1469-1479. (PMID: 30798327) Sci Rep. 2020 Sep 15;10(1):15083. (PMID: 32934298) J Natl Cancer Inst. 2018 Apr 1;110(4):379-389. (PMID: 29106591) RNA. 2018 Oct;24(10):1339-1350. (PMID: 29970596) Cell Death Dis. 2017 Nov 9;8(11):e3168. (PMID: 29120411) Expert Rev Anticancer Ther. 2014 Aug;14(8):865-8. (PMID: 24928581) RNA. 2005 Aug;11(8):1281-90. (PMID: 16043508) Nucleic Acids Res. 2016 Sep 19;44(16):7511-26. (PMID: 27317694) Environ Sci Pollut Res Int. 2020 May;27(15):17468-17480. (PMID: 31129903) Int J Mol Sci. 2019 Jun 15;20(12):. (PMID: 31208067) Int J Cancer. 2019 Apr 15;144(8):1941-1953. (PMID: 30350310) Nat Cell Biol. 2019 May;21(5):552-559. (PMID: 31048770) Clin Oncol (R Coll Radiol). 2005 Sep;17(6):418-24. (PMID: 16149284) Front Cell Dev Biol. 2021 Jun 04;9:672248. (PMID: 34178999) Cell. 2016 Oct 20;167(3):816-828.e16. (PMID: 27745969) Mol Cell Biol. 1995 Oct;15(10):5376-88. (PMID: 7565688) Aging (Albany NY). 2020 Jun 11;12(12):11667-11684. (PMID: 32526707) Cancer Sci. 2014 Sep;105(9):1135-41. (PMID: 24975429) Nat Chem Biol. 2011 Oct 16;7(12):885-7. (PMID: 22002720) PLoS One. 2009 Dec 23;4(12):e8419. (PMID: 20037631) Cancer Cell Int. 2018 Dec 3;18:196. (PMID: 30524204) Cell Rep. 2015 Oct 13;13(2):267-76. (PMID: 26440895) Cancer Manag Res. 2018 Aug 28;10:2965-2975. (PMID: 30214291) Tumour Biol. 2017 Jul;39(7):1010428317708546. (PMID: 28714361) J Immunol Res. 2021 Aug 23;2021:6149558. (PMID: 34476262) Front Mol Biosci. 2020 Apr 24;7:68. (PMID: 32391379) Cell Cycle. 2017;16(23):2259-2271. (PMID: 29135329) Oncotarget. 2017 Jun 13;8(24):39417-39429. (PMID: 28455960) J Biol Chem. 2017 Mar 10;292(10):4326-4335. (PMID: 28167531) EMBO Rep. 2021 Apr 7;22(4):e50128. (PMID: 33605073) Mol Ther. 2020 Oct 7;28(10):2177-2190. (PMID: 32621798) DNA Cell Biol. 2021 Mar;40(3):513-522. (PMID: 33416433) Hum Mol Genet. 2010 Oct 15;19(R2):R162-8. (PMID: 20798109) Mol Cell. 2017 Dec 7;68(5):993-1005.e9. (PMID: 29107537) New Phytol. 2018 Mar;217(4):1535-1550. (PMID: 29218722) Mol Cancer. 2019 Jun 22;18(1):110. (PMID: 31228940) Front Oncol. 2021 Jun 09;11:657466. (PMID: 34195072) Cell Death Dis. 2021 Mar 19;12(4):298. (PMID: 33741902) Wiley Interdiscip Rev Syst Biol Med. 2009 Sep-Oct;1(2):202-209. (PMID: 20835992) Cancer Lett. 2013 Oct 10;339(2):159-66. (PMID: 23791884) RNA. 2012 Dec;18(12):2269-76. (PMID: 23097428) Nature. 2016 Apr 21;532(7599):329-33. (PMID: 27027282) J Clin Invest. 2019 Dec 2;129(12):5343-5356. (PMID: 31682236) Cell. 2011 Apr 15;145(2):178-81. (PMID: 21496640) Biochim Biophys Acta Rev Cancer. 2020 Dec;1874(2):188417. (PMID: 32828887) Pathol Res Pract. 2019 Nov;215(11):152666. (PMID: 31606241) Genes (Basel). 2019 Feb 05;10(2):. (PMID: 30764532) Nucleic Acids Res. 2019 Nov 18;47(20):10801-10814. (PMID: 31552420) J Oncol. 2021 Aug 20;2021:1814266. (PMID: 34457003) J Biol Chem. 2009 Aug 21;284(34):22803-14. (PMID: 19509282) Nature. 2016 Feb 25;530(7591):441-6. (PMID: 26863196) Mol Cancer. 2019 Jun 24;18(1):112. (PMID: 31230592) Diagn Pathol. 2017 Jan 21;12(1):12. (PMID: 28109322) Am J Cancer Res. 2019 Oct 01;9(10):2156-2169. (PMID: 31720080) RNA. 2000 May;6(5):755-67. (PMID: 10836796) Nat Med. 2013 Feb;19(2):209-16. (PMID: 23291631) Annu Rev Neurosci. 1996;19:27-52. (PMID: 8833435) Int J Mol Sci. 2020 Sep 04;21(18):. (PMID: 32899690) PLoS One. 2015 Mar 09;10(3):e0119539. (PMID: 25751421) Mol Cancer. 2019 Oct 13;18(1):142. (PMID: 31607270) Cancer Res. 2014 Feb 1;74(3):840-51. (PMID: 24302582) Proc Natl Acad Sci U S A. 2000 May 9;97(10):5173-8. (PMID: 10779558) IUBMB Life. 2021 Oct;73(10):1235-1243. (PMID: 34314547) Front Oncol. 2021 Apr 22;11:645745. (PMID: 33968744) DNA Cell Biol. 2020 Oct;39(10):1767-1778. (PMID: 32833542) Theranostics. 2020 Oct 26;10(26):12072-12089. (PMID: 33204330) Prog Nucleic Acid Res Mol Biol. 2005;79:299-338. (PMID: 16096031) J Biomed Sci. 2018 Oct 23;25(1):74. (PMID: 30352587) Sci Adv. 2020 Jun 17;6(25):eaba5136. (PMID: 32596459) Mol Cell. 2018 Jan 4;69(1):62-74.e4. (PMID: 29276085) Biochem Biophys Res Commun. 2007 Jul 27;359(2):258-62. (PMID: 17533110) Science. 2008 Jun 20;320(5883):1643-7. (PMID: 18566288) |
| فهرسة مساهمة: | Keywords: N 1-methyladenosine; N 6-methyladenosine; RNA modification; adenosine-to-inosine editing; alternative polyadenylation; head and neck squamous cell carcinoma; immunotherapy |
| تواريخ الأحداث: | Date Created: 20211213 Latest Revision: 20211215 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC8657411 |
| DOI: | 10.3389/fphar.2021.779779 |
| PMID: | 34899345 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1663-9812 |
|---|---|
| DOI: | 10.3389/fphar.2021.779779 |